Checkpoint Therapeutics Overview
- Founded
- 2014
- Status
- Public
- Employees
- 8
- Stock Symbol
- CKPT
- Investments
- 1
- Share Price
- $3.62
- (As of Friday Closing)
Checkpoint Therapeutics General Information
Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Contact Information
Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 2 Gansevoort Street
- 9th Floor
- New York, NY 10014
- United States
+1 (781) 000-0000
Checkpoint Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.62 | $3.73 | $1.05 - $4.50 | $246M | 67.9M | 681K | -$0.46 |
Checkpoint Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 159,020 | 79,166 | 32,365 | 75,553 |
| Revenue | 1,067 | 1,708 | 3,506 | 1,725 |
| EBITDA | (21,816) | (24,850) | (36,515) | (22,775) |
| Net Income | (21,682) | (24,714) | (36,367) | (22,677) |
| Total Assets | 42,645 | 26,966 | 24,899 | 21,413 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Checkpoint Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Checkpoint Therapeutics‘s full profile, request access.
Request a free trialCheckpoint Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisiti
Biotechnology
New York, NY
8
As of 2019
00000
00000000
00000
000000
quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000 000000000
Wilmington, DE
0000
As of 0000
00000000000
00000000
uat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pa
000000000000000
West Conshohocken, PA
00
As of 0000
000.00
000000 - 000
000.00
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialCheckpoint Therapeutics Competitors (9)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Incyte | Corporate Backed or Acquired | Wilmington, DE | 0000 | 00000000000 | ||
| 00000000 000000000 | Corporation | West Conshohocken, PA | 00 | 000.00 | 000000 - 000 | 000.00 |
| 000000 00000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000 00000 | |
| 000000000 00000000 | Venture Capital-Backed | Pittsburgh, PA | 00 | 000.00 | 0000000000 | 000.00 |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00000 | 000.00 | 00000000000 |
Checkpoint Therapeutics Executive Team (3)
Checkpoint Therapeutics Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00000000 000 | Checkpoint Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
Checkpoint Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialCheckpoint Therapeutics Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 (0000000 | 000000000 00000 00 | Buildings and Property |